Hem D Shukla
University of Maryland, USA
Posters-Accepted Abstracts: J Mol Biomark Diagn
Pancreatic cancer is one of the most aggressive human malignancies and ninth leading cause of cancer death in the world. Estimated new cases and deaths from pancreatic cancer in 2013 in the United States would be 45,220 and deaths 38,460. Most patients diagnosed with pancreatic cancer die within 6 months, and only 4% survive 5 years after diagnosis. Pancreatic cancer is characterized by colossal local invasion and early metastatic growth to the liver and regional lymph nodes. Expression of Nrf2 was up-regulated in oxidatively stressed BxPC-3 cell line and ductal adenocarcinomas. Furthermore the BxPC-3 cell line responds to stress signals and resist chemotherapeutic interventions and have shown drug resistance. The Nrf2 has also been implicated in proliferation in certain pancreatic adenocarinomas. Normally, ROS levels are tightly controlled by an inducible antioxidant program that responds to cellular stressors and is predominantly regulated by the transcription factor Nrf2. It was also identified the presence of a number of gene products involved in integrin signaling pathways. The comparative proteomic analysis using Protein Center and Ingenuity Pathway Analysis have shown the activation of DNA repair pathway genes like RAD50, ApeX, damage-specific DNA binding protein which have the capability to repair DNA damage. The activation of NRF2 transcriptional factor in BxPC-3 treated cells shows that it may bind to the DNA at the location of the Antioxidant Response Element (ARE) or also called hARE (Human Antioxidant Response Element) which is the master regulator of the total antioxidant system. These results may have some promise in therapeutic intervention in the treatment of pancreatic cancer adenocarcinoma.
Email: hshukla@rx.umaryland.edu
Molecular Biomarkers & Diagnosis received 2054 citations as per Google Scholar report
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 